Halozyme Therapeutics Inc (HALO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
N/A
Employees:
281
11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121-1345
(858) 794-8889

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other d...

Data derived from most recent annual or quarterly report
Market Cap 4.673 Billion Shares Outstanding142.335 Million Avg 30-day Volume 814.495 Thousand
P/E Ratio37.9723 Dividend Yield0.0 EPS1.53
Price to Revenue18.6941 Debt to Equity12.9266 EBITDA217.18 Million
Price to Book Value91.6138 Operating Margin59.8357 Enterprise Value6.302 Billion
Current Ratio8.767 EPS Growth3.073 Quick Ratio7.938
1 Yr BETA 1.4787 52-week High/Low 56.4 / 31.79 Profit Margin49.2308
Operating Cash Flow Growth238.1522 Altman Z-Score5.5711 Free Cash Flow to Firm 99.959 Million

Are you looking for this stock instead?

View SEC Filings from HALO instead.

View recent insider trading info

Funds Holding HALO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HALO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

82 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

58.1 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TORLEY HELEN PRESIDENT AND CEO

  • Officer
  • Director
687,160 2021-11-08 14

MATSUI CONNIE

  • Director
181,983 2021-11-05 2

LABARRE MICHAEL J. SVP, CHIEF TECHNICAL OFFICER

  • Officer
156,846 2021-10-12 12

MATSUDA MASARU SVP, GENERAL COUNSEL

  • Officer
26,932 2021-09-04 3

BIZZARI JEAN-PIERRE

  • Director
52,544 2021-08-25 2

HENDERSON JEFFREY WILLIAM

  • Director
52,839 2021-05-05 1

POSARD MATTHEW L.

  • Director
128,983 2021-05-05 1

DALY JAMES M

  • Director
26,232 2021-05-05 1

CONNAUGHTON BERNADETTE

  • Director
32,013 2021-05-05 1

KELLEY KENNETH J

  • Director
179,833 2021-04-14 4

SUN ELAINE D SVP, CHIEF FINANCIAL OFFICER

  • Officer
44,618 2021-04-01 3

STELZER LAURIE SVP, CHIEF FINANCIAL OFFICER

  • Officer
126,167 2020-02-22 0

HICKEY BENJAMIN SVP, CHIEF COMMERICAL OFFICER

  • Officer
13,226 2019-10-01 0

CHONDROS DIMITRIOS SVP, CHIEF MEDICAL OFFICER

  • Officer
38,584 2019-08-03 0

ARMOUR ALISON A. SVP, RESEARCH & DEVELOPMENT

  • Officer
0 2019-06-03 0

LEONHARDT HARRY J SVP, GC

  • Officer
66,373 2019-04-13 0

KIRK RANDAL J

  • 10% Owner
No longer subject to file 2018-08-24 0

GERGEN MARK J SVP, CHIEF OPERATING OFFICER

  • Officer
0 2017-02-22 0

COUNTOURIOTIS ATHENA SVP AND CHIEF MEDICAL OFFICER

  • Officer
0 2017-02-22 0

FALBERG KATHRYN E

  • Director
358,253 2016-05-04 0

RAMSAY DAVID A VP AND CHIEF FINANCIAL OFFICER

  • Officer
364,320 2015-02-04 0

PATTON JOHN STUART

  • Director
179,876 2014-08-19 0

ENGLER ROBERT

  • Director
273,176 2014-08-14 0

LIU JEAN I VP & GENERAL COUNSEL

  • Officer
0 2014-02-06 0

SHAFFER JAMES P VP & CHIEF COMMERCIAL OFFICER

  • Officer
0 2014-02-06 0

FROST GREGORY IAN CEO, PRESIDENT

  • Officer
  • Director
3,641,380 2013-12-11 0

SHEPARD H. MICHAEL VP, CHIEF SCIENTIFIC OFFICER

  • Officer
13,198 2013-08-19 0

GUSTAFSON KURT A VICE PRESIDENT AND CFO

  • Officer
0 2013-02-04 0

FALLON WILLIAM J VP, MANUFACTURING & OPERATIONS

  • Officer
0 2011-05-10 0

LITTLE ROBERT J VP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2010-02-04 0

LIM JONATHAN E CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2010-02-04 0

LEFF JONATHAN A VP, CHIEF MEDICAL OFFICER

  • Officer
0 2009-08-06 0

THORNTON STEVEN T

  • Director
30,000 2008-05-08 0

YOCUM RICHARD C VP-CLINICAL DEVELOPMENT

  • Officer
0 2008-02-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

TORLEY HELEN - Director - Officer PRESIDENT AND CEO

2021-11-08 18:22:22 -0500 2021-11-08 S 37,775 $39.62 d 549,385 direct yes -1.1137 -0.9583 0.9065 4 -1.1137 2

TORLEY HELEN - Director - Officer PRESIDENT AND CEO

2021-11-08 18:22:22 -0500 2021-11-08 M 50,000 $14.66 d 150,000 direct yes

TORLEY HELEN - Director - Officer PRESIDENT AND CEO

2021-11-08 18:22:22 -0500 2021-11-08 M 50,000 $14.66 a 587,160 direct yes -1.1137 -0.9583 0.9065 4 -1.1137 2

TORLEY HELEN - Director - Officer PRESIDENT AND CEO

2021-11-08 18:22:22 -0500 2021-11-08 S 12,225 $40.42 d 537,160 direct yes -1.1137 -0.9583 0.9065 4 -1.1137 2

MATSUI CONNIE - Director

2021-11-05 17:59:41 -0400 2021-11-05 S 19,452 $40.13 d 194,531 direct -2.0796 -3.1448 0.0 1 -3.1702 3

MATSUI CONNIE - Director

2021-11-05 17:59:41 -0400 2021-11-05 S 12,548 $40.77 d 181,983 direct -2.0796 -3.1448 0.0 1 -3.1702 3

LABARRE MICHAEL J. - Officer SVP, CHIEF TECHNICAL OFFICER

2021-10-12 19:06:18 -0400 2021-10-12 M 8,050 $13.10 a 156,846 direct 4.1192 3.4417 -4.4173 10.3252 18 -5.122 30

LABARRE MICHAEL J. - Officer SVP, CHIEF TECHNICAL OFFICER

2021-10-12 19:06:18 -0400 2021-10-12 M 8,050 d 0 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
HALOZYME THERAPEUTICS INC HALO 2021-12-07 17:45:03 UTC -0.2667 0.3367 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 17:15:03 UTC -0.2667 0.3367 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 16:45:04 UTC -0.2537 0.3237 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 16:15:04 UTC -0.2537 0.3237 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 15:45:03 UTC -0.2537 0.3237 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 15:15:04 UTC -0.2537 0.3237 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 14:45:04 UTC -0.1879 0.2579 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 14:15:03 UTC -0.1879 0.2579 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 13:45:03 UTC -0.1879 0.2579 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 13:15:03 UTC -0.1879 0.2579 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-07 12:45:04 UTC -0.1879 0.2579 4800000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 22:15:04 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 21:45:02 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 21:15:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 20:45:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 20:15:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 19:45:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 19:15:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 18:45:03 UTC -0.1879 0.2579 4900000
HALOZYME THERAPEUTICS INC HALO 2021-12-06 18:15:03 UTC -0.1879 0.2579 4900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Index Plus All-Cap Fund HALO -11.0 shares, $-197.89 2020-03-31 N-PORT
Morningstar Funds Trust- Morningstar Alternatives Fund HALO -5249.0 shares, $-216941.17 2021-07-30 N-PORT
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund HALO -485525.0 shares, $-20066748.25 2021-07-31 N-PORT
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund HALO -6045.0 shares, $-245910.6 2021-09-30 N-PORT
Guidestone Funds- Strategic Alternatives Fund HALO -3825.0 shares, $-155601.0 2021-09-30 N-PORT

Elevate your investments